116 related articles for article (PubMed ID: 26637882)
21. Her2
Krishna BM; Chaudhary S; Panda AK; Mishra DR; Mishra SK
Sci Rep; 2018 May; 8(1):7427. PubMed ID: 29743533
[TBL] [Abstract][Full Text] [Related]
22. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia.
Zúbor P; Vojvodová A; Danko J; Kajo K; Szunyogh N; Lasabová Z; Biringer K; Visnovský J; Dókus K; Galajda P; Plank L
Neoplasma; 2006; 53(1):49-55. PubMed ID: 16416013
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.
Akisik E; Dalay N
Exp Mol Pathol; 2004 Jun; 76(3):260-3. PubMed ID: 15126109
[TBL] [Abstract][Full Text] [Related]
24. HER2Ile655Val Single Nucleotide Polymorphism Associated with Early-Onset Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis.
Nguyen Thanh T; Nguyen Tran BS; Hoang Thi AP; Tran Binh T; Ba Nguyen T; Le Minh T; Nguyen Vu QH; Dang Cong T
Asian Pac J Cancer Prev; 2021 Jan; 22(1):11-18. PubMed ID: 33507673
[TBL] [Abstract][Full Text] [Related]
25. Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis.
Dahabreh IJ; Murray S
Cancer Epidemiol; 2011 Dec; 35(6):503-9. PubMed ID: 21474413
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
27. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
[TBL] [Abstract][Full Text] [Related]
28. Her2 genotype and breast cancer progression in Korean women.
An HJ; Kim NK; Oh D; Kim SH; Park MJ; Jung MY; Kang H; Kim SG; Lee KP; Lee KS
Pathol Int; 2005 Feb; 55(2):48-52. PubMed ID: 15693849
[TBL] [Abstract][Full Text] [Related]
29. Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects.
Ma Y; Yang J; Zhang P; Liu Z; Yang Z; Qin H
Breast Cancer Res Treat; 2011 Jan; 125(1):237-41. PubMed ID: 20524057
[TBL] [Abstract][Full Text] [Related]
30. HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer.
Ozturk O; Canbay E; Kahraman OT; Fatih Seyhan M; Aydogan F; Celik V; Uras C
Mol Biol Rep; 2013 Feb; 40(2):1813-8. PubMed ID: 23086302
[TBL] [Abstract][Full Text] [Related]
31. ERBB2 genetic polymorphism and breast cancer risk in Chinese women: a population-based case-control study.
Qu S; Cai Q; Gao YT; Lu W; Cai H; Su Y; Wang SE; Shu XO; Zheng W
Breast Cancer Res Treat; 2008 Jul; 110(1):169-76. PubMed ID: 17687647
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
33. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity.
Beauclair S; Formento P; Fischel JL; Lescaut W; Largillier R; Chamorey E; Hofman P; Ferrero JM; Pagès G; Milano G
Ann Oncol; 2007 Aug; 18(8):1335-41. PubMed ID: 17693647
[TBL] [Abstract][Full Text] [Related]
34. Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer.
Puputti M; Sihto H; Isola J; Butzow R; Joensuu H; Nupponen NN
Cancer Genet Cytogenet; 2006 May; 167(1):32-8. PubMed ID: 16682283
[TBL] [Abstract][Full Text] [Related]
35. HER2 polymorphisms and breast cancer in Tunisian women.
Kallel I; Kharrat N; Al-fadhly S; Rebai M; Khabir A; Boudawara TS; Rebaï A
Genet Test Mol Biomarkers; 2010 Feb; 14(1):29-35. PubMed ID: 19929405
[TBL] [Abstract][Full Text] [Related]
36. Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer.
Cresti N; Lee J; Rourke E; Televantou D; Jamieson D; Verrill M; Boddy AV
Eur J Cancer; 2016 Mar; 55():27-37. PubMed ID: 26773371
[TBL] [Abstract][Full Text] [Related]
37. Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.
Stanton SE; Ward MM; Christos P; Sanford R; Lam C; Cobham MV; Donovan D; Scheff RJ; Cigler T; Moore A; Vahdat LT; Lane ME; Chuang E
BMC Cancer; 2015 Apr; 15():267. PubMed ID: 25885598
[TBL] [Abstract][Full Text] [Related]
38. No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer.
Wang L; Habuchi T; Takahashi T; Kamoto T; Zuo T; Mitsumori K; Tsuchiya N; Sato K; Ogawa O; Kato T
Int J Cancer; 2002 Feb; 97(6):787-90. PubMed ID: 11857355
[TBL] [Abstract][Full Text] [Related]
39. Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients.
Satiroglu-Tufan NL; Bir F; Calli-Demirkan N
World J Gastroenterol; 2006 May; 12(20):3283-7. PubMed ID: 16718853
[TBL] [Abstract][Full Text] [Related]
40. HER2 polymorphism and breast cancer risk in Portugal.
Pinto D; Vasconcelos A; Costa S; Pereira D; Rodrigues H; Lopes C; Medeiros R
Eur J Cancer Prev; 2004 Jun; 13(3):177-81. PubMed ID: 15167216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
